Emicizumab in Severe Hemophilia A: Clinical and Patient Determinants of Transition Within a Standardized Program. [PDF]
Blydt-Hansen I, Bech M, Jackson S.
europepmc +1 more source
Repeated hemorrhagic ulcers of the esophagus associated with acquired hemophilia A: A case report. [PDF]
Saito M +8 more
europepmc +1 more source
Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A. [PDF]
Schimansky IM +15 more
europepmc +1 more source
New therapies in hemophilia: extend the half-life, mimic, or rebalance? [PDF]
Reding MT.
europepmc +1 more source
COVID-19-Associated Acquired Hemophilia A With an Exceptionally High Inhibitor Titer: A Case of Remission and Overwhelming Sepsis. [PDF]
Pathak S.
europepmc +1 more source
Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study. [PDF]
Olasupo OO +15 more
europepmc +1 more source
Monochorionic diamniotic twin brothers with severe hemophilia A: a case report. [PDF]
Riboldi L, Coscia A, Peila C.
europepmc +1 more source
More real-world evidence on the impact of emicizumab. [PDF]
Teitel J.
europepmc +1 more source
Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials. [PDF]
Ishaque R +14 more
europepmc +1 more source

